



ASX and Media Release

CAVATAK Cancer Immunotherapy: Progress in Phase 2 Melanoma Trial

Data to be presented at the American Society of Clinical Oncology (ASCO) Conference

15 May 2014, Sydney, Australia: An update on Viralytics Limited (ASX:VLA, OTC:VRACY) progress in the Phase 2 trial of CAVATAK™ in the treatment of late stage melanoma (the CALM study) has been accepted for poster presentation at ASCO, the world's foremost oncology conference.

The presentation will feature as a highlighted poster in the "Developmental Therapeutics – Immunotherapy" session at the annual meeting of ASCO in Chicago from May 30-June 3, 2014.

More than 25,000 oncology professionals are expected to attend ASCO including major pharmaceutical company representatives.

The Viralytics highlighted poster presentation is entitled:

Abstract 3031: "CALM study: A phase II study of an intratumorally delivered oncolytic immunotherapeutic agent, Coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma"

Dr Robert Andtbacka, lead study investigator from the Huntsman Cancer Institute, Utah, USA, will present the poster and an international panel will discuss an accompanying slide deck in a separate session, both on June 2.

Following the presentation, the poster and associated slides will be available on the Viralytics website. A copy of the abstract is now available on the ASCO website at:

http://abstracts2.asco.org/AbstView_144_134927.html

"ASCO is the preeminent international forum to expand awareness of the growing body of CAVATAK™ clinical data." said Dr Malcolm McColl, Chief Executive Officer of Viralytics. "We are delighted we have been selected to participate in the highlighted posters session at ASCO and look forward to the opportunity to provide an update on our CALM study."

Enquiries:

Dr Malcolm McColl
Chief Executive Officer
02 9988 4000

Mr Rudi Michelson
Monsoon Communications
03 9620 3333

About Viralytics Ltd:

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. Viralytics' lead investigational product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not



limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells. Together this mechanism of action is known as oncolytic immunotherapy. CAVATAK™'s preferential targeting of cancer cells creates the potential for a more tolerable cancer treatment.

The company has completed enrolment in a Phase 2 clinical trial of intratumourally administered CAVATAK™ in the treatment of Late stage Melanoma (the CALM study), at multiple prestigious cancer clinics in the US.

In addition, Viralytics has commenced a Phase 1/2 trial of CAVATAK™ delivered systemically (intravenously). This trial, referred to as the STORM (Systemic Treatment Of RMalignancies) study is enrolling patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with existing chemotherapies in one of the above cancer types. The STORM trial is being conducted at three UK cancer centres.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market.